We’ve had to make this difficult decision in order to protect vital NHS services and also to test ways of delivering this new ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

Most people taking popular drugs like Ozempic and Wegovy to lose weight have shed significant pounds. But obesity experts say ...

New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

President Joe Biden wants Medicare and Medicaid to cover weight-loss drugs, a proposal that would expand access to the costly ...

Obesity is one of the greatest public health issues facing the NHS and weight loss drugs, such as tirzepatide, are an important tool in helping people lose weight while also reducing the risk of other ...